AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11085201
Drug: Fluvoxamine ≤300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine ≤300 mg/day for 6 to 8 weeks
Trial: 11085201
Drug: Fluvoxamine ≤300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine ≤300 mg/day for ≥8 weeks
Trial: 8397881
Drug: Alcohol subjects
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol subjects received sufficient alcohol to raise their blood alcohol level to .07 mg %
Trial: 3453187
Drug: Diuretics (mainly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (mainly chlorthalidone)
Trial: 29392743
Drug: PPD 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPD 1% pet. (6 mg)
Trial: 29392743
Drug: PPD 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPD 0.3% pet. (20 mg)
Trial: 29392743
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses (PPD 1% and PPD 0.3%)
Trial: 26866638
Drug: Active medication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medication (MED; n = 50)
Trial: 26866638
Drug: Supportive-expressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive therapy (SET; n = 49)
Trial: 26866638
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill (PBO; n = 50)
Trial: 24176534
Drug: Supportive-expressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive therapy (SET)
Trial: 26866638
Drug: Active medication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medication (MED)
Trial: 25448672
Drug: IBPB associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBPB associated with Intravenous‐inhalation combined anesthesia (group NB)
Trial: 25448672
Drug: Intravenous‐inhalation combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous‐inhalation combined anesthesia (group CI)
Trial: 16451305
Drug: Chemical agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical agents incorporated in dentifrice or mouth rinse formulations
Trial: 10696890
Drug: 0.2 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 percent glyceryl trinitrate ointment
Trial: 11938776
Drug: Carvedilol (10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (10mg to 40mg once daily)
Trial: 11938776
Drug: Atenolol (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50mg to 100mg once daily)
Trial: 9031394
Drug: Regimen-I: artemether
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen-I: artemether (300 mg) plus pyrimethamine (100 mg) on the first day, then placebo on the two consecutive days
Trial: 9031394
Drug: Regimen-II: artemether
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen-II: artemether (300 mg) plus pyrimethamine (100 mg) on the first day, then artemether (150 mg) plus pyrimethamine (50 mg) on the second day, and placebo on the third day
Trial: 9031394
Drug: Regimen-III: artemether
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen-III: artemether (300 mg) plus pyrimethamine (100 mg) on the first day, then artemether (150 mg) plus pyrimethamine (50 mg) on the second and third days
Trial: 6347753
Drug: Flurbiprofen (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (50 mg four times a day)
Trial: 24532525
Drug: Dexmedetomidine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.2 μg/(kg·h)⁻¹)
Trial: 23422630
Drug: 6% triphala
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% triphala mouthwash, 15 ml twice a day
Trial: 23422630
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine mouthwash, 15 ml twice a day
Trial: 23422630
Drug: Plain water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain water rinse, twice a day
Trial: 20347681
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical treatment (BMT) alone.
Trial: 12358658
Drug: Intramuscular clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular clonidine (2 microg x kg(‐1))
Trial: 1688913
Drug: Dextran 40
RxNorm normalized name: Dextran 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran 40 (500 ml per session) during 3 weeks
Trial: 1688913
Drug: Placebo treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatments for 3 weeks
Trial: 7387900
Drug: Prednisolone 40
RxNorm normalized name: prednisolone 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 40 mg daily with gradual reduction over a period of 4 weeks
Trial: 7387900
Drug: Carbamazepine 100
RxNorm normalized name: carbamazepine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 100 mg four times daily
Trial: 24415640
Drug: Rituximab maintenance
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab maintenance (375 mg/m2, 12 doses)
Trial: 24415640
Drug: Chlorambucil (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorambucil (8 mg/m2/day, days 1-7) and Rituximab (375 mg/m2 on day 1 of cycle 3, 500 mg/m2 for cycles 4-8)
Trial: 22829268
Drug: Donepezil 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 3 mg/day
Trial: 22829268
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg/day and 10 mg/day
Trial: 19193706
Drug: Probiotic yogurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yogurt containing Bifidobacterium animalis subsp. lactis DN-173010 (2 x 10(8) CFU/g), 200 g once daily for 2 weeks
Trial: 19193706
Drug: Control yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control yogurt without viable bacteria, 200 g once daily for 2 weeks
Trial: 17185016
Drug: Intravenous ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketoprofen 1mg/kg i.v. at skin closure, and at 8 and 16 hours after surgery
Trial: 14975544
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg o.d. added to statin therapy (fluvastatin 40 mg)
Trial: 11185669
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (statin therapy only)
Trial: 14975544
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg o.d. added to statin therapy
Trial: 9555595
Drug: Risperidone 8
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone 8 mg once daily
Trial: 9555595
Drug: Risperidone 4
RxNorm normalized name: risperidone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 4 mg twice daily
Trial: 8200551
Drug: Adrenaline alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline alone (3-10 ml of 1:100,000 adrenaline)
Trial: 3312133
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (50 mg elemental zinc/day)
Trial: 28557676
Drug: Intervention based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention based on the Valencia Model of Waking Hypnosis combined with Cognitive‐Behavioral Therapy
Trial: 26084292
Drug: PCH (trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCH (trastuzumab and paclitaxel weekly combined with carboplatin weekly)
Trial: 21943032
Drug: Docetaxel (DCT)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (DCT) 20 mg/m2/week and continuous fluorouracil (5-FU) 200 mg/m2/day plus concurrent radiotherapy
Trial: 21943032
Drug: Docetaxel (DCT)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (DCT) 20 mg/m2/week and cisplatin (CDDP) 20 mg/m2 plus concurrent radiotherapy
Trial: 19047492
Drug: Nurse-led hospice
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led hospice collaborative; specific details on dosage and duration not available.
Trial: 19047492
Drug: Classroom instruction;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classroom instruction; specific details on dosage and duration not available.
Trial: 19047492
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of classroom and hospice experiences; specific details on dosage and duration not available.
Trial: 7600600
Drug: Denmark II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denmark II lyophilized vaccines
Trial: 2223928
Drug: m-chlorophenylpiperazine (m-CPP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-chlorophenylpiperazine (m-CPP), 80 mg/day
Trial: 24037083
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg orally once daily
Trial: 19526744
Drug: Nidotherapy enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nidotherapy enhanced assertive treatment (up to 12 sessions)
Trial: 17341178
Drug: Multimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatment therapy
Trial: 16134605
Drug: S (+)
RxNorm normalized name: Guardian Paracetamol Extra Plus (+) (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S (+) ‐ismer of ibuprofen suppository (one suppository per day for 3 days)
Trial: 16134605
Drug: Ibuprofen suppository
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen suppository (one suppository per day for 3 days)
Trial: 11512111
Drug: Amitriptyline 25
RxNorm normalized name: amitriptyline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 25 mg/night
Trial: 11512111
Drug: Placebo 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 25 mg/night
Trial: 9990417
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% gel applied immediately after washing
Trial: 9990417
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% gel applied 20-30 min after washing
Trial: 3378661
Drug: Oxaprozin 1200
RxNorm normalized name: Oxaprozin
DrugBank: Oxaprozin (DB00991)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxaprozin 1200 mg/day
Trial: 3378661
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 100 mg/day
Trial: 25505221
Drug: Strategy training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategy training (n = 15, 10 sessions as adjunct to usual inpatient rehabilitation)
Trial: 25505221
Drug: Reflective listening
RxNorm normalized name: Listerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reflective listening (n = 15, same dose)
Trial: 6307458
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia (Group G)
Trial: 15008994
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human TSH (rhTSH) 0.45 mg pretreatment before RAI treatment
Trial: 30137527
Drug: Radioactive iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radioactive iodine (RAI) treatment
Trial: 11319712
Drug: Vegetable oil-based
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable oil-based stanols (2.6 g sitostanol plus 1.2 g campestanol daily)
Trial: 11319712
Drug: Wood-based stanols
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wood-based stanols (3.7 g sitostanol plus 0.3 g campestanol daily)
Trial: 3508327
Drug: Naproxen 375
RxNorm normalized name: naproxen 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 375 mg twice daily for 2 weeks
Trial: 3508327
Drug: Naproxen 750
RxNorm normalized name: naproxen 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 750 mg twice daily for 2 weeks
Trial: 3508327
Drug: Naproxen 375
RxNorm normalized name: naproxen 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 375 mg twice daily for 2 weeks (continued from phase I)
Trial: 14978133
Drug: Grass pollen
RxNorm normalized name: grass pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass pollen immunotherapy (Phleum pratense, Phl P) for 2 years
Trial: 14978133
Drug: Post-immunotherapy serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-immunotherapy serum
Trial: 10768243
Drug: HP-eradication therapy
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP-eradication therapy
Trial: 8222742
Drug: Controlled-release metoclopramide
RxNorm normalized name: metoclopramide Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release metoclopramide ('Gastrobid Continus' tablets) 15 mg given twice daily
Trial: 8222742
Drug: Normal-release metoclopramide
RxNorm normalized name: metoclopramide Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-release metoclopramide ('Maxolon') 10 mg given 4-times daily
Trial: 8222742
Drug: Controlled-release metoclopramide
RxNorm normalized name: metoclopramide Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release metoclopramide
Trial: 3544647
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nifedipine (n = 20)
Trial: 20015104
Drug: S-tenatoprazole-Na 90
RxNorm normalized name: sulfacetamide sodium Ophthalmic Solution [S.O.S.S.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-tenatoprazole-Na 90 mg
Trial: 20015104
Drug: S-tenatoprazole-Na 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-tenatoprazole-Na 60 mg
Trial: 20015104
Drug: S-tenatoprazole-Na 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-tenatoprazole-Na 30 mg
Trial: 12620168
Drug: Diuretics (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics (single or combination)
Trial: 1359319
Drug: FK‐224 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK‐224 (4 mg)
Trial: 3925929
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (600 mg)
Trial: 3925929
Drug: Carbamazepine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (100 mg)
Trial: 3925929
Drug: Phenytoin (1500-2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin (1500-2000 mg)
Trial: 15367726
Drug: Carbamazepine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (800 mg)
Trial: 29954374
Drug: Placebo (430
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (430 mg olive oil/day)
Trial: 29330573
Drug: Low TT
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low TT (430 mg TT/day, 70% purity)
Trial: 29330573
Drug: High TT
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High TT (860 mg TT/day, 70% purity)
Trial: 26739235
Drug: Mini-tablets (MTs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-tablets (MTs)
Trial: 26739235
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating mini-tablet (ODMT)
Trial: 21371548
Drug: Conventional tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tablet (CT)
Trial: 26739235
Drug: Conventional orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional orally disintegrating tablet (ODT)
Trial: 22479925
Drug: Glucantime (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucantime (5 days of intralesional administration)
Trial: 12119306
Drug: Pharmacotherapy for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy for bulimia nervosa
Trial: 12119306
Drug: Combined pharmacotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined pharmacotherapy and short-term psychotherapy
Trial: 9717330
Drug: Amoxicillin-clavulanate for
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate for 24 hours
Trial: 8023058
Drug: Beta-carotene levels
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene levels in patients (0.36 microgram/g biopsy)
Trial: 8023058
Drug: Alpha-tocopherol levels
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-tocopherol levels in patients (237.5 micrograms/g biopsy)
Trial: 8023058
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplement consumption
Trial: 2455151
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR (to 240 mg b.i.d.)
Trial: 2455151
Drug: Metoprolol (to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (to 100 mg b.i.d.)
Trial: 27532880
Drug: MusicGlove therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MusicGlove therapy
Trial: 23325911
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) intervention delivered by a nurse therapist, up to 12 sessions.
Trial: 23325911
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) intervention.
Trial: 21523723
Drug: Dasatinib (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (administered orally or via percutaneous feeding gastrostomy)
Trial: 21523723
Drug: Dasatinib (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (administered via percutaneous feeding gastrostomy)
Trial: 19907042
Drug: Revascularization plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revascularization plus medical therapy
Trial: 16951015
Drug: Topical retinoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinoid
Trial: 16951015
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (topical retinoid + antimicrobial agent)
Trial: 16951015
Drug: Topical retinoids
RxNorm normalized name: tocopheryl retinoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinoids (maintenance therapy)
Trial: 15234416
Drug: Tedisamil 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tedisamil 0.4 mg/kg
Trial: 15234416
Drug: Tedisamil 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tedisamil 0.6 mg/kg
Trial: 9377539
Drug: Dextroamphetamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (10 mg doses)
Trial: 30977770
Drug: Baclofen (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (30 mg/day or 75 mg/day)
Trial: 26899588
Drug: Early medication
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early medication change (EMC) strategy: venlafaxine XR for study days 15‐56; lithium augmentation for days 29‐56 if sustained non‐improvement on day 28.
Trial: 26899588
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU): continuation of escitalopram; non-responders on day 28 switched to venlafaxine XR for four weeks (days 29‐56).
Trial: 24548534
Drug: Community Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community Health Worker (CHW) intervention consisting of five monthly group educational sessions, two one-on-one visits, and follow-up phone calls over six months.
Trial: 20197015
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of normal-dose telmisartan (40 mg) and low-dose hydrochlorothiazide (12.5 mg) once daily for 12 weeks
Trial: 17284896
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion technique for measuring glomerular filtration rate and renal plasma flow
Trial: 16899775
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of atorvastatin per day
Trial: 25720557
Drug: Concurrent neck
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent neck dissection during TORS (control group)
Trial: 23091109
Drug: Bortezomib 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m², thalidomide 100 mg, and dexamethasone 40 mg (VTD)